US › Healthcare

Biomea Fusion Inc (BMEA)

US · Healthcare · Biotechnology

$1.79+2.87%

Last close · 2026-09-17

Latest quarter · ended 2026-06-30

Revenue

Net profit

$-8.3M

EPS

$-0.12

EPS estimate

$-0.21

EPS came in at -0.12 against a street estimate of -0.21 — a beat of 42.9%.

Key statistics

Market cap

$126.1M

Forward P/E

0.0

P/B

10.78

Book value

$0.17

EPS (TTM)

$-0.17

52-week high

$2.99

52-week low

$0.87

50-day MA

$1.45

200-day MA

$1.40

Beta

-0.24

Analyst view

Analysts rate Biomea Fusion Inc a buy (7 buy, 2 hold, 0 sell out of 9) with an average price target of $6.50.

Shareholding

Insiders

7.15%

Institutions

40.02%

Largest institutional holders

Fund	Stake
FMR Inc	12.16%
Vanguard Capital Management, LLC	3.58%
Aisling Capital Management LP	2.83%
Renaissance Technologies Corp	1.81%
Marshall Wace Asset Management Ltd	1.65%
Fideuram - Intesa Sanpaolo Private Banking Spa	1.00%
Mariner Wealth Advisors LLC	0.90%
BlackRock Inc	0.88%

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Biomea Fusion Inc — free to start.

Google Play App Store

Other Healthcare companies

Eli Lilly and Company Johnson & Johnson AbbVie Inc Merck & Company Inc UnitedHealth Group Incorporated Novartis AG ADR AstraZeneca PLC Thermo Fisher Scientific Inc Amgen Inc Novo Nordisk A/S Gilead Sciences Inc Abbott Laboratories

Data updated 2026-09-18.